For research and educational purposes only. Not medical advice.

Mazdutide Reference

Educational, not medical advice reference for Mazdutide: GLP-1, Fat Loss; regulatory status, evidence posture, source review, and schedule notes. Also known…

Reference summary

Published Phase 2 and in-progress Phase 3 data support investigational status. pepSmart displays mazdutide only as trial-context educational content.

Categories
GLP-1, Fat Loss
Aliases
IBI362, LY3305677, GLP-1/glucagon dual agonist
Evidence posture
human — Human trial data exist, but mazdutide remains investigational.
Regulatory status
Investigational. Mazdutide is a GLP-1/glucagon dual receptor agonist developed by Innovent Biologics with Phase 3 obesity and type 2 diabetes programs (GLORY program) primarily based in China. There is no FDA-approved drug label, and mazdutide is not on FDA's approved bulk-substances list for compounding.
Content review status
investigational verified

Selected public sources